Study of first-line treatment for advanced liposarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a first-line treatment for people with advanced or unresectable dedifferentiated liposarcoma that has spread. The goal is to find a therapy that works before other treatments are used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have been diagnosed with dedifferentiated liposarcoma that has spread and you have not had any systemic therapy yet
- Your cancer has not spread to the brain
- You are in good general health (ECOG score 0-1) and your organs are working well
- You are willing to use effective contraception during and for 8 weeks after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
This trial studies a treatment called lifileucel that uses your own immune cells to fight the cancer. It is for people with a type of soft tissue sarcoma that has not responded to previous treatments.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
Hear when a new Dedifferentiated Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.